NCT00579514Active, not recruiting
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Source: ClinicalTrials.gov · Last updated 7 Apr 2026
Brief summary (registry, in English)
The basic premise of this research proposal is to determine whether there is any significant association between germline polymorphisms and cancers of colon, bladder, breast, testicular, prostate, ovaries, kidney, lung, lymphoid organs, and head and neck. This is an exploratory study designed to generate hypotheses for further research.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 21081 (actual)
- First submitted
- 20 Dec 2007
- Start date
- Mar 2000
- Primary completion date
- Mar 2027
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Prostate cancer, Kidney cancer, Bladder cancer, Lung cancer, Colorectal cancer, Ovarian cancer, Childhood cancers
- NCT number
- NCT00579514
What you commit to
- Study type: Interventional
- Participants enrolled: 21081
- From Mar 2000 to the primary completion date, Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- MSKCC patients without a histologic diagnosis of cancer of the breast, bladder, kidney, colon, testicles, lungs, prostate, or lymphoid malignancy (including all types of lymphoma) will not be eligible for the AMDeC sponsored component of the study.
Who the study is looking for
- Patients with a histologic diagnosis of cancer of the colon, breast, bladder, kidney, testicles, lungs, prostate, head and neck, or lymphoid organs, who have donated a diagnostic blood sample as either an inpatient or outpatient at MSKCC.
- All patients who have two or more histologic diagnoses of the same primary tumor type involving the above sites.
- Patients of Ashkenazi Jewish ancestry with a histologic diagnosis of cancer of any type.
- Samples ascertained as part of protocol 98-024A(1) are also eligible for ascertainment in this study.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.